Sign in to view content

PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration

David T.W. Wong, MD, FRCS(C), FASRS

Video
Published 2025

Related

Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2022
Future DME Therapeutics
Updates from the Field
2017
PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results
John A. Wells, MD, FACS
Updates from the Field
2025

Category: AMD-Neovascular

See more